Free Trial

AbbVie (ABBV) Stock Price, News & Analysis

AbbVie logo
$192.32 -2.68 (-1.37%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$192.38 +0.06 (+0.03%)
As of 07/11/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AbbVie Stock (NYSE:ABBV)

Key Stats

Today's Range
$191.16
$194.00
50-Day Range
$177.30
$196.04
52-Week Range
$163.81
$218.66
Volume
4.99 million shs
Average Volume
6.30 million shs
Market Capitalization
$339.71 billion
P/E Ratio
81.84
Dividend Yield
3.41%
Price Target
$211.29
Consensus Rating
Moderate Buy

Company Overview

AbbVie Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

ABBV MarketRank™: 

AbbVie scored higher than 90% of companies evaluated by MarketBeat, and ranked 93rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 16 buy ratings, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AbbVie has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about AbbVie's stock forecast and price target.
  • Earnings Growth

    Earnings for AbbVie are expected to grow by 13.57% in the coming year, from $12.31 to $13.98 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AbbVie is 81.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.84.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AbbVie is 81.84, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.18.

  • Price to Earnings Growth Ratio

    AbbVie has a PEG Ratio of 1.29. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AbbVie has a P/B Ratio of 101.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AbbVie's valuation and earnings.
  • Percentage of Shares Shorted

    0.91% of the float of AbbVie has been sold short.
  • Short Interest Ratio / Days to Cover

    AbbVie has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AbbVie has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    AbbVie pays a meaningful dividend of 3.44%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AbbVie has been increasing its dividend for 53 years.

  • Dividend Coverage

    The dividend payout ratio of AbbVie is 279.15%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, AbbVie will have a dividend payout ratio of 46.92% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

  • Read more about AbbVie's dividend.
  • Percentage of Shares Shorted

    0.91% of the float of AbbVie has been sold short.
  • Short Interest Ratio / Days to Cover

    AbbVie has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AbbVie has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    AbbVie has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 103 news articles for AbbVie this week, compared to 62 articles on an average week.
  • Search Interest

    101 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • MarketBeat Follows

    34 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AbbVie insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.25% of the stock of AbbVie is held by insiders.

  • Percentage Held by Institutions

    70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AbbVie's insider trading history.
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

3 No-Brainer Dividend Stocks to Buy In July
3 Dividend Growth Stocks to Buy and Hold
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

ABBV Stock Analysis - Frequently Asked Questions

AbbVie's stock was trading at $177.70 at the beginning of 2025. Since then, ABBV shares have increased by 8.2% and is now trading at $192.32.

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Friday, April, 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.06. The firm's quarterly revenue was up 8.4% compared to the same quarter last year.
Read the conference call transcript
.

AbbVie subsidiaries include these companies: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and more.

AbbVie's top institutional shareholders include Assenagon Asset Management S.A. (0.25%), Kingstone Capital Partners Texas LLC (0.18%), Swedbank AB (0.11%) and Mn Services Vermogensbeheer B.V. (0.04%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Roxanne S Austin, Carrie C Strom, Elaine K Sorg, Scott T Reents, Perry C Siatis and Kevin K Buckbee.
View institutional ownership trends
.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC).

Company Calendar

Record date for 5/15 Dividend
4/15/2025
Ex-Dividend for 5/15 Dividend
4/15/2025
Last Earnings
4/25/2025
Dividend Payable
5/15/2025
Today
7/12/2025
Record date for 8/15 Dividend
7/15/2025
Ex-Dividend for 8/15 Dividend
7/15/2025
Next Earnings (Estimated)
7/31/2025
Dividend Payable
8/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:ABBV
CIK
1551152
Employees
55,000
Year Founded
2013

Price Target and Rating

High Price Target
$250.00
Low Price Target
$180.00
Potential Upside/Downside
+9.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
27 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.35
Trailing P/E Ratio
81.84
Forward P/E Ratio
15.62
P/E Growth
1.29
Net Income
$4.28 billion
Net Margins
7.31%
Pretax Margin
6.31%
Return on Equity
412.03%
Return on Assets
13.11%

Debt

Debt-to-Equity Ratio
44.14
Current Ratio
0.76
Quick Ratio
0.64

Sales & Book Value

Annual Sales
$57.37 billion
Price / Sales
5.92
Cash Flow
$14.73 per share
Price / Cash Flow
13.06
Book Value
$1.90 per share
Price / Book
101.22

Miscellaneous

Outstanding Shares
1,766,403,000
Free Float
1,761,987,000
Market Cap
$339.71 billion
Optionable
Optionable
Beta
0.48

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:ABBV) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners